Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Phase 1 data showing its fixed-dose hepatitis C regimen bemnifosbuvir/ruzasvir (BEM/RZR) has a low risk of drug-drug interactions with common medicines including omeprazole, digoxin and rosuvastatin.
Atea also presented preclinical data for AT-587, a potential first-in-class hepatitis E antiviral with high in vitro potency and in vivo efficacy.
Atea Pharmaceuticals (Nasdaq: AVIR) will present three abstracts at the EASL 2026 Congress in Barcelona from May 27–30. Two posters cover clinical data on its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C, while a top poster highlights preclinical data for AT-587, Atea’s lead hepatitis E candidate.
Atea Pharmaceuticals (Nasdaq: AVIR) reported first quarter 2026 results and clinical progress. Cash, cash equivalents and marketable securities were $256.0 million at March 31, 2026, down from $301.8 million. Net loss was $45.4 million (basic and diluted loss per share $0.57).
Phase 3 HCV trials remain on track, with C-BEYOND topline data expected mid-2026 and C-FORWARD around year-end 2026. Preclinical data support AT-587 as lead HEV candidate, with Phase 1 initiation targeted for mid-2026.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on May 12, 2026 at 4:30 p.m. ET to report first quarter results for the period ended March 31, 2026 and provide a business update. The webcast will be archived on the company's investor site approximately two hours after the call and remain available for at least 90 days.
ReAlta Life Sciences (NASDAQ:AVIR) appointed Howard Berman, Ph.D. as Chairman and CEO and Kia Motesharei, Ph.D. as President and COO on March 24, 2026.
The hires add capital markets, deal-making, and late-stage clinical development experience as ReAlta advances pegtarazimod into late-stage trials for HIE and other indications.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Q4 and full-year 2025 results and a business update. The company completed enrollment in C-BEYOND (>880 patients) and expects C-BEYOND topline results mid-2026 and C-FORWARD results around year-end 2026 for the bemnifosbuvir/ruzasvir HCV regimen.
Cash and investments were $301.8M at 12/31/2025; AT-587 for hepatitis E is expected to enter clinical development mid-2026.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Thursday, March 5, 2026 at 4:30 p.m. ET to report fourth quarter and full year results for the period ended December 31, 2025, and to provide a business update.
Participants may register for the call, join via telephone using conference ID 10206566, or listen on the company's Investor Relations website at ir.ateapharma.com. An archive of the webcast will be posted about two hours after the call and remain available for at least 90 days.
Atea Pharmaceuticals (Nasdaq: AVIR) presented preclinical data at CROI 2026 showing AT-587 and AT-2490 are potent in vitro inhibitors of hepatitis E virus (HEV), with AT-587 selected as the lead candidate. AT-587 and AT-2490 were 30–150-fold more potent versus sofosbuvir and ribavirin and produced high levels of active metabolite in human liver cells with no observed toxicity. Atea plans to initiate a Phase 1 clinical program mid-2026. Poster: 596; CROI Feb 22–25, 2026.
Atea Pharmaceuticals (NASDAQ: AVIR) will present 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference and provided program and pipeline updates on Jan 8, 2026. The company reported $301.8 million cash and investments at Dec 31, 2025, with a cash runway expected through 2027. Atea is advancing a global Phase 3 program for a fixed-dose combination of bemnifosbuvir and ruzasvir for HCV: C-BEYOND (North America) is fully enrolled with >880 patients and topline results are expected mid-2026; C-FORWARD (outside North America) expects enrollment completion mid-2026 and topline results around year-end 2026. Phase 2 data showed 98% SVR12 (per-protocol) for an 8-week regimen. Atea selected AT-587 for HEV and anticipates initiating a Phase 1 study mid-2026.
Atea Pharmaceuticals (Nasdaq: AVIR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT in San Francisco.
Jean-Pierre Sommadossi, PhD, CEO and founder, and other Atea management will present. A live webcast will be available on the company's investor site at https://ir.ateapharma.com, with an archived webcast available for at least 90 days after the event.